GlassScriptPhysician profile
Matthew S O Hern
NPI 1821098625
$2,582.01
in general payments reported to CMS, 2019-2025
16 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $40.15 · 2022: $425 · 2023: $588 · 2024: $442 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,187.84 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $307.72 | 2019-2025 | Impella |
| Pfizer INC. | $159.67 | 2019-2025 | |
| Abbott Laboratories | $152.96 | 2024-2025 | Diamondback Coronary, Navitor, Pressurewire |
| Novartis Pharmaceuticals Corporation | $124.13 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $116.79 | 2019-2023 | Xarelto |
| Amgen INC. | $104.75 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.69 | 2019-2025 | Lifevest |
| Biotronik INC. | $76.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.90 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $58.75 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $44.13 | 2022-2023 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $39.66 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $20.79 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $12.98 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew O Hern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.